Compare ALAR & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALAR | GNTA |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | Israel | Italy |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.1M | 34.0M |
| IPO Year | 2018 | 2021 |
| Metric | ALAR | GNTA |
|---|---|---|
| Price | $7.84 | $1.44 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $27.00 | N/A |
| AVG Volume (30 Days) | 82.2K | ★ 92.8K |
| Earning Date | 11-26-2025 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $36,305,000.00 | N/A |
| Revenue This Year | $31.17 | N/A |
| Revenue Next Year | $30.14 | N/A |
| P/E Ratio | $47.33 | ★ N/A |
| Revenue Growth | ★ 15.03 | N/A |
| 52 Week Low | $5.45 | $1.28 |
| 52 Week High | $18.00 | $10.00 |
| Indicator | ALAR | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 31.52 | 36.07 |
| Support Level | $7.46 | $1.28 |
| Resistance Level | $7.93 | $1.68 |
| Average True Range (ATR) | 0.35 | 0.17 |
| MACD | 0.23 | 0.02 |
| Stochastic Oscillator | 59.09 | 27.42 |
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.